Dorit Ben-Moha, DO
Adult Medicine · Jericho, NYNPI 1831288851
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,689 of the $2,039 with a category attached, or 82.8%. It is spread thinly across 17 manufacturers, the largest accounting for just 22.0% — the pattern of someone who eats at a lot of different presentations.
Across 107 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$448
- Novo Nordisk$397
- Lilly USA, LLC$286
- Amgen$144
- Esperion Therapeutics, Inc.$121
- Ardelyx, Inc.$105
- plus $538 from 11 others
What the payments were for
- Food & beverage$1,68983%
- Education$35017%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 10 | $448 |
| Novo Nordisk | 22 | $397 |
| Lilly USA, LLC | 19 | $286 |
| Amgen | 9 | $144 |
| Esperion Therapeutics, Inc. | 7 | $121 |
| Ardelyx, Inc. | 6 | $105 |
| AstraZeneca | 7 | $103 |
| Amarin Pharma, Inc. | 5 | $80 |
| Pfizer | 4 | $66 |
| Baxter Healthcare | 3 | $54 |
| GSK | 3 | $48 |
| Merck | 3 | $46 |
| Boehringer Ingelheim | 2 | $42 |
| Johnson & Johnson | 3 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Bausch Health US, LLC | 1 | $20 |
| Seqirus USA Inc | 1 | $15 |
How this compares
$2,039 in reported general payments places this provider in the 70th percentile of 101 adult medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 105 | $80,960 |
| OzempicSemaglutide | 79 | $79,947 |
| LinzessLinaclotide | 138 | $78,682 |
| Diclofenac Sodium | 28 | $71,553 |
| MounjaroTirzepatide | 44 | $48,844 |
| ProliaDenosumab | 26 | $46,143 |
| JanuviaSitagliptin Phosphate | 51 | $40,729 |
| XareltoRivaroxaban | 53 | $35,684 |
| FarxigaDapagliflozin Propanediol | 35 | $29,108 |
| TrulicityDulaglutide | 31 | $27,291 |
| Midodrine Hcl | 199 | $25,022 |
| Famotidine | 401 | $23,585 |
| VascepaIcosapent Ethyl | 51 | $18,831 |
| JardianceEmpagliflozin | 28 | $16,549 |
| TradjentaLinagliptin | 26 | $15,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $66 | $80,960105 claims |
| Novo NordiskOzempic | $397 | $79,94779 claims |
| Lilly USA, LLCMounjaro, Trulicity | $286 | $76,13575 claims |
| AmgenProlia | $144 | $46,14326 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $103 | $41,98659 claims |
| MerckJanuvia | $46 | $40,72951 claims |
| Johnson & JohnsonXarelto | $36 | $35,68453 claims |
| Boehringer IngelheimJardiance, Tradjenta | $42 | $31,59154 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Arexvy | $48 | $25,17355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 101 adult medicine providers in New York.
Other adult medicine in Jericho
- Michael AlaimoMalverne$18K
- Vipin OhriWarsaw$14K
- Yuqing ZhangFlushing$13K
- Chidambaranathan ChandrasekaranPatchogue$13K
- Adam CarpentieriMassapequa$11K
- Cary DanielBrooklyn$10K
- Janaki KanumilliMineola$9K
- Zeeshan KhanOceanside$9K
- Thomas MolnarJamaica$8K
- Tehmina NaveedPlainview$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.